Study in JAMA Network Open Examines Association Between the Percentage of US Drug Sales Subject to Inflation Penalties and the Extent of Drug Price Increases


 

September 11, 2020
 
Sean Dickson, JD, MPH1
JAMA Netw Open. 2020;3(9):e2016388. doi:10.1001/jamanetworkopen.2020.16388

Policy makers have proposed levying penalties for drug price increases that are higher than the rate of inflation for drugs covered in the US Medicare program, but research is lacking regarding the ways in which manufacturers might respond to those penalties. An understanding of manufacturers’ responses to existing inflation penalties could inform such policy discussions.

PLEASE READ THE FULL STUDY ON JAMANETWORK.COM